Abstract
The paraoxonase (PON) gene cluster contains at least three members, including PON1, PON2, and PON3, located on chromosome 7q21.3–22.1. Until now there has been little insight into the role of the respective gene products in human physiology and pathology. However, emerging evidence from biochemical and genetic experiments is providing clues about the role(s) of the products of these genes, which indicates that PON(s) acts as important guardians against cellular damage from toxic agents, such as organophosphates, oxidized lipids in the plasma low-density lipoproteins. In parallel, substantial data have been published on the association between the polymorphisms of PON(s) and coronary heart disease. It has become clear that the polymorphisms significantly affect the prevalence of coronary heart disease. However, the associations between the PON(s) polymorphisms and most of these conditions were found to be inconsistent when additional populations were investigated. This contribution provides an overview of the status of research of each of the three genes and the available association studies and the potential problems in interpreting the data. We also review the current evidence on the association between PON(s) polymorphisms and diseases other than coronary heart disease and some metabolic quantitative phenotypes, such as plasma lipoproteins, plasma glucose, and birthweight. Finally, we suggest directions for the future that might elucidate the role of the PON genetic polymorphisms in this potentially important function of PON(s) and the role in coronary heart disease and other related diseases.
Similar content being viewed by others
Abbreviations
- AD :
-
Alzheimer’s dementia
- Apo :
-
Apolipoprotein
- CHD :
-
Coronary heart disease
- HDL :
-
High-density lipoprotein
- LDL :
-
Low-density lipoprotein
- PD :
-
Parkinson’s disease
- PON :
-
Paraoxonase
References
Costa LG, Cole TB, Jarvik GP and Furlong CE (2003) Functional genomics of the paraoxonase (PON1) polymorphisms: effects on pesticide sensitivity, cardiovascular disease and drug metabolism. Annu Rev Med 54:371–392
Costa LG, Furlong CE (2003) Paraoxonase (PON1) in health and disease: basic and clinical aspects. Kluwer Norwell, pp 165–183
Mackness B, Durrington PN, Mackness MI (2002) The paraoxonase gene family and coronary heart disease. Curr Opin Lipidol 13:357–362
Osei-Hyiaman D, Hou L, Mengbai F, Zhiyin R, Zhiming Z, Kano K (2001) Coronary artery disease risk in Chinese type 2 diabetics: is there a role for paraxonase 1 gene (Q192R) polymorphism? Eur J Endocrinol 144:639–644
Ito T, Yasue H, Yoshimura M, Nakamura S, Nakayama M, Shimasaki Y, Harada E, Mizuno Y, Kawano H, Ogawa H (2002) Paraoxonase gene Gln192Arg (Q192R) polymorphism is associated with coronary artery spasm. Hum Genet 110:89–94
Zhang Z, Zhang L, Yepes M, Jiang Q, Li Q, Arniego P, Coleman TA, Lawrence DA, Chopp M (2002) Adjuvant treatment with neuroserpin increases the therapeutic window for tissue-type plasminogen activator administration in a rat model of embolic stroke. Circulation 106:740–745
Cherry N, Mackness M, Durrington P, Povey A, Dippnall M, Smith T, Mackness B (2002) Paraoxonase (PON1) polymorphisms in farmers attributing ill health to sheep dip. Lancet 359:763–764
Worth J (2002) Paraoxonase polymorphisms and organophosphates. Lancet 360:802–803
Allebrandt KV, Souza RL, Chautard-Freire-Maia EA (2002) Variability of the paraoxonase gene (PON1) in Euro- and Afro-Brazilians. Toxicol Appl Pharmacol 180:151–156
Voetsch B, Benke KS, Damasceno BP, Siqueira LH, Loscalzo J (2002) Paraoxonase 192 Gln→Arg polymorphism: an independent risk factor for nonfatal arterial ischemic stroke among young adults. Stroke 33:1459–1464
Yamada M, Sodeyama N, Itoh Y, Otomo E, Matsushita M, Mizusawa H (2002) No association of paraoxonase genotype or atherosclerosis with cerebral amyloid angiopathy. Stroke 33:896–900
Arca M, Ombres D, Montali A, Campagna F, Mangieri E, Tanzilli G, Campa PP, Ricci G, Verna R, Pannitteri G (2002) PON1 L55M polymorphism is not a predictor of coronary atherosclerosis either alone or in combination with Q192R polymorphism in an Italian population. Eur J Clin Invest 32:9–15
Sangvanich P, Mackness B, Gaskell SJ, Durrington P, Mackness M (2003) The effect of high-density lipoproteins on the formation of lipid/protein conjugates during in vitro oxidation of low-density lipoprotein. Biochem Biophys Res Commun 300:501–506
Malin R, Knuuti J, Janatuinen T, Laaksonen R, Vesalainen R, Nuutila P, Jokela H, Laakso J, Jaakkola O, Solakivi T, Lehtimaki T (2001) Paraoxonase gene polymorphisms and coronary reactivity in young healthy men. J Mol Med 79:449–458
Rowles J, Scherer SW, Xi T, Majer M, Nickle DC, Rommans JM, Popov KM, Harris RA, Riebow NL, Xia J (1996) Cloning and characterisation of PDK4 on 7q21.3 encoding a fourth pyruvate dehydrogenase kinase isoenzyme in human. J Biol Chem 271:22376–22382
Mackness B, Durrington PN, Abuashia B, Boulton AJM, Mackness MI (2000) Low paraoxonase activity in type II diabetes complicated by retinopathy. Clin Sci (Colch) 98:355–363
Draganov DI, Stetson PL, Watson CE, Billecke SS, La Du BN (2000) Rabbit serum paraoxonase 3 (PON3) is a high density lipoprotein-associated lactonase and protects low density lipoprotein against oxidation. J Biol Chem 275:33435–33442
Josse D, Ebel C, Stroebel D, Fontaine A, Borges F, Echalier A, Baud D, Renault F, Le Maire M, Chabrieres E, Masson P (2002) Oligomeric states of the detergent-solubilized human serum paraoxonase (PON1). J Biol Chem 277:33386–33397
Durrington PN, Mackness B, Mackness MI (2001) Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 21:473–480
La Du BN (1996) Structural and functional diversity of paraoxonases. Nat Med 2:1186–1187
Deakin S, Leviev I, Gomaraschi M, Calabresi L, Franceschini G, James RW (2002) Enzymatically active paraoxonase-1 is located at the external membrane of producing cells and released by a high affinity, saturable, desorption mechanism. J Biol Chem 277:4301–4308
Navab M, Berliner JA, Subbanagounder G, Hama S, Lusis AJ, Castellani LW, Reddy S, Shih D, Shi W, Watson AD, Van Lenten BJ, Vora D, Fogelman AM (2001) HDL and the inflammatory response induced by LDL-derived oxidized phospholipids. Arterioscler Thromb Vasc Biol 21:481–488
Shih DM, Xia YR, Wang XP, Miller E, Castellani LW, Subbanagounder G, Cheroutre H, Faull KF, Berliner JA, Witztum JL, Lusis AJ (2000) Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. J Biol Chem 275:17527–17535
Shih DM, Gu L, Xia YR, Navab M, Li WF, Hama S, Castellani LW, Furlong CE, Costa LG, Fogelman AM, Lusis AJ (1998) Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 394:284–287
Tward A, Xia YR, Wang XP, Shi YS, Park C, Castellani LW, Lusis AJ, Shih DM (2002) Decreased atherosclerotic lesion formation in human serum paraoxonase transgenic mice. Circulation 106:484–490
Oda MN, Bielicki JK, Ho TT, Berger T, Rubin EM, Forte TM (2002) Paraoxonase 1 overexpression in mice and its effect on high-density lipoproteins. Biochem Biophys Res Commun 290:921–927
Van Lenten BJ, Wagner AC, Navab M, Fogelman AM (2001) Oxidized phospholipids induce changes in hepatic paraoxonase and ApoJ but not monocyte chemoattractant protein-1 via interleukin-6. J Biol Chem 276:1923–1929
Ahmed Z, Babaei S, Maguire GF, Draganov D, Kuksis A, La Du BN, Connelly PW (2003) Paraoxonase-1 reduces monocyte chemotaxis and adhesion to endothelial cells due to oxidation of palmitoyl, linoleoyl glycerophosphorylcholine. Cardiovasc Res 57:225–231
Ahmed Z, Ravandi A, Maguire GF, Emili A, Draganov D, La Du BN, Kuksis A, Connelly PW (2001) Apolipoprotein A-I promotes the formation of phosphatidylcholine core aldehydes that are hydrolyzed by paraoxonase (PON-1) during high density lipoprotein oxidation with a peroxynitrite donor. J Biol Chem 276:24473–24481
Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN (1998) Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest 101:1581–1590
Ahmed Z, Ravandi A, Maguire GF, Emili A, Draganov D, La Du BN, Kuksis A, Connelly PW (2002) Multiple substrates for paraoxonase-1 during oxidation of phosphatidylcholine by peroxynitrite. Biochem Biophys Res Commun 290:391–396
Aviram M, Hardak E, Vaya J, Mahmood S, Milo S, Hoffman A, Billicke S, Draganov D, Rosenblat M (2000) Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities. Circulation 101:2510–2517
Jarvik GP, Tsai NT, McKinstry LA, Wani R, Brophy VH, Richter RJ, Schellenberg GD, Heagerty PJ, Hatsukami TS, Furlong CE (2002) Vitamin C and E intake is associated with increased paraoxonase activity. Arterioscler Thromb Vasc Biol 22:1329–1333
Arrol S, Mackness MI, Durrington PN (1996) Low density lipoprotein associated with enzymes and the prevention of low-density lipoprotein oxidation. Eur J Lab Med 4:33–48
Rodrigo L, Hernandez AF, Lopez-Caballero JJ, Gil F, Pla A (2001) Immunohistochemical evidence for the expression and induction of paraoxonase in rat liver, kidney, lung and brain tissue. Implications for its physiological role. Chem Biol Interact 137:123–137
Cole TB, Jampsa RL, Walter BJ, Arndt TL, Richter RJ, Shih DM, Tward A, Lusis AJ, Jack RM, Costa LG, Furlong CE (2003) Expression of human paraoxonase (PON1) during development. Pharmacogenetics 13:357–364
Feingold KR, Memon RA, Moser AH (1998) Paraoxonase activity in the serum and hepatic mRNA levels decrease during the acute phase response. Atherosclerosis 139:307–315
Aviram M, Rosenblat M, Billecke S (1999) Human serum paraoxonase (PON1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic Biol Med 26:892–904
Ferre N, Camps J, Cabre M (2001) Hepatic paraoxonase activity alterations and free radical production in rats with experimental cirrhosis. Metabolism 50:997–1000
Gonzalvo MC, Gil F, Hernandez AF et al (1997) Inhibition of paraoxonase activity in human liver microsomes by exposure to EDTA, metals and mercurials Chem Biol Interact 105:169–179
James RW, Leviev I, Righetti A (2000) Smoking is associated with reduced serum paraoxonase activity and concentration in patients with coronary artery disease. Circulation 101:2252–2257
Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE (1993) The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet 3:73–76
Adkins S, Gan KN, Mody M, La Du BN (1993) Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet 52:598–608
Watson CE, Draganov DI, Billecke SS, Bisgaier CL, La Du BN (2001) Rabbits possess a serum paraoxonase polymorphism similar to the human Q192R. Pharmacogenetics 11:123–134
Imai Y, Morita H, Kurihara H, Sugiyama T, Kato N, Ebihara A, Hamada C, Kurihara Y, Shindo T, Oh-hashi Y, Yazaki Y (2000) Evidence for association between paraoxonase gene polymorphisms and atherosclerotic diseases. Atherosclerosis 149:435–442
Ko YL, Ko YS, Wang SM, Hsu LA, Chang CJ, Chu PH, Cheng NJ, Chen WJ, Chiang CW, Lee YS (1998) The Gln-Arg 191 polymorphism of the human paraoxonase gene is not associated with the risk of coronary artery disease among Chinese in Taiwan. Atherosclerosis 141:259–264
Ferre N, Tous M, Paul A, Zamora A, Vendrell JJ, Bardaji A, Camps J, Richart C, Joven J (2002) Paraoxonase Gln-Arg (192) and Leu-Met (55) gene polymorphisms and enzyme activity in a population with a low rate of coronary heart disease. Clin Biochem 35:197–203
Furlong CE, Cole TB, Jarvik GP, Costa LG (2002) Pharmacogenomic considerations of the paraoxonase polymorphisms. Pharmacogenomics 3:341–348
Leviev I, Poirier O, Nicaud V, Evans A, Kee F, Arveiler D, Morrisson C, Cambien F, James RW (2002) High expressor paraoxonase PON1 gene promoter polymorphisms are associated with reduced risk of vascular disease in younger coronary patients. Atherosclerosis 161:463–467
Leviev I, Kalix B, Brulhart Meynet MC, James RW (2001) The paraoxonase PON1 promoter polymorphism C (-107) T is associated with increased serum glucose concentrations in non-diabetic patients. Diabetologia 44:1177–1183
Leviev I, Righetti A, James RW (2001) Paraoxonase promoter polymorphism T (-107) C and relative paraoxonase deficiency as determinants of risk of coronary artery disease. J Mol Med 79:457–463
Brophy VH, Jampsa RL, Clendenning JB, McKinstry LA, Jarvik GP, Furlong CE (2001) Effects of 5’ regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. Am J Hum Genet 68:1428–1436
Brophy VH, Hastings MD, Clendenning JB, Richter RJ, Jarvik GP, Furlong CE (2001) Polymorphisms in the human paraoxonase (PON1) promoter. Pharmacogenetics 11:77–84
Leviev I, James RW (2000) Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler Thromb Vasc Biol 20:516–521
James RW, Leviev I, Righetti A (2000) Smoking is associated with reduced serum paraoxonase activity and concentration in patients with coronary artery disease. Circulation 101:2252–2257
Hedrick CC, Hassan K, Hough GP, Yoo JH, Simzar S, Quinto CR, Kim SM, Dooley A, Langi S, Hama SY, Navab M, Witztum JL, Fogelman AM (2000) Short-term feeding of atherogenic diet to mice results in reduction of HDL and paraoxonase that may be mediated by an immune mechanism. Arterioscler Thromb Vasc Biol 20:1946–1952
Van Lenten BJ, Wagner AC, Nayak DP, Hama S, Navab M, Fogelman AM (2001) High-density lipoprotein loses its anti-inflammatory properties during acute influenza a infection. Circulation 103:2283–2288
Van Lenten BJ, Wagner AC, Anantharamaiah GM, Garber DW, Fishbein MC, Adhikary L, Nayak DP, Hama S, Navab M, Fogelman AM (2002) Influenza infection promotes macrophage traffic into arteries of mice that is prevented by D-4F, an apolipoprotein A-I mimetic peptide. Circulation 106:1127–1132
De Roos NM, Schouten EG, Scheek LM, van Tol A, Katan MB (2002) Replacement of dietary saturated fat with trans fat reduces serum paraoxonase activity in healthy men and women. Metabolism 51:1534–1537
Freese R, Alfthan G, Jauhiainen M, Basu S, Erlund I, Salminen I, Aro A, Mutanen M (2002) High intakes of vegetables, berries, and apples combined with a high intake of linoleic or oleic acid only slightly affect markers of lipid peroxidation and lipoprotein metabolism in healthy subjects. Am J Clin Nutr 76:950–960
Rantala M, Silaste ML, Tuominen A, Kaikkonen J, Salonen JT, Alfthan G, Aro A, Kesaniemi YA (2002) Dietary modifications and gene polymorphisms alter serum paraoxonase activity in healthy women. J Nutr 132:3012–3017
Hegele RA (1999) Paraoxonase genes and disease. Ann Med 31:217–224
Leus FR, Zwart M, Kastelein JJ, Voorbij HA (2001) PON2 gene variants are associated with clinical manifestations of cardiovascular disease in familial hypercholesterolemia patients. Atherosclerosis 154:641–649
Ikeda T, Obayashi H, Hasegawa G, Nakamura N, Yoshikawa T, Imamura Y, Koizumi K, Kinoshita S (2001) Paraoxonase gene polymorphisms and plasma oxidized low-density lipoprotein level as possible risk factors for exudative age-related macular degeneration. Am J Ophthalmol 132:191–195
Fanella S, Harris SB, Young TK, Hanley AJ, Zinman B, Connelly PW, Hegele RA (2000) Association between PON1 L/M55 polymorphism and plasma lipoproteins in two Canadian aboriginal populations. Clin Chem Lab Med 38:413–420
Malin R, Laaksonen R, Knuuti J, Janatuinen T, Vesalainen R, Nuutila P, Lehtimaki T (2001) Paraoxonase genotype modifies the effect of pravastatin on high-density lipoprotein cholesterol. Pharmacogenetics 11:625–633
Watzinger N, Schmidt H, Schumacher M, Schmidt R, Eber B, Fruhwald FM, Zweiker R, Kostner GM, Klein W (2002) Human paraoxonase1 gene polymorphisms and the risk of coronary heart disease: a community-based study. Cardiology 98:116–122
Mackness B, Davies GK, Turkie W, Lee E, Roberts DH, Hill E, Roberts C, Durrington PN, Mackness MI (2001) Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype? Arterioscler Thromb Vasc Biol 21:1451–1457
Bonafe M, Marchegiani F, Cardelli M, Olivieri F, Cavallone L, Giovagnetti S, Pieri C, Marra M, Antonicelli R, Troiano L, Gueresi P, Passeri G, Berardelli M, Paolisso G, Barbieri M, Tesei S, Lisa R, De Benedictis G, Franceschi C (2002) Genetic analysis of paraoxonase (PON1) locus reveals an increased frequency of Arg192 allele in centenarians. Eur J Hum Genet 10:292–296
Garin MC, James RW, Dussoix P, Blanche H, Passa P, Froguel P, Ruiz J (1997) Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J Clin Invest 99:62–66
Murphy MM, Vilella E, Ceruelo S, Figuera L, Sanchez M, Camps J, Cuco G, Ferre N, Labad A, Tasevska N, Arija V, Joven J, Fernandez-Ballart J (2002) The MTHFR C677T, APOE, and PON55 gene polymorphisms show relevant interactions with cardiovascular risk factors. Clin Chem 48:372–375
Jarvik GP, Rozek LS, Brophy VH (2000) Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1192 or PON155 genotype. Arterioscler Thromb Vasc Biol 20:2441–2447
James RW, Leviev I, Ruiz J (2000) Promoter polymorphism T (-107) C of the paraoxonase PON1 gene is a risk factor for coronary heart disease in type 2 diabetic patients. Diabetes 49:1390–1393
Ng CJ, Wadleigh DJ, Gangopadhyay A, Hama S, Grijalva VR, Navab M, Fogelman AM, Reddy ST (2001) Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein. J Biol Chem 276:44444–44449
Mochizuki H, Scherer SW, Xi T, Nickle DC, Majer M, Huizenga JJ, Tsui LC, Prochazka M (1998) Human PON2 gene at 7q21.3: cloning, multiple mRNA forms, and missense polymorphisms in the coding sequence. Gene 213:149–157
Boright AP, Connelly PW, Brunt JH, Scherer SW, Tsui LC, Hegele RA (1998) Genetic variation in paraoxonase-1 and paraoxonase-2 is associated with variation in plasma lipoproteins in Alberta Hutterites. Atherosclerosis 139:131–136
Gunnarsdottir I, Birgisdottir BE, Thorsdottir I, Gudnason V, Benediktsson R (2002) Size at birth and coronary artery disease in a population with high birth weight. Am J Clin Nutr 76:1290–1294
Bhopal R, Fischbacher CM (2002) Many South Asian people probably need pre-diabetes care. BMJ 325:965
Cassell PG, Jackson AE, North BV, Evans JC, Syndercombe-Court D, Phillips C, Ramachandran A, Snehalatha C, Gelding SV, Vijayaravaghan S, Curtis D, Hitman GA (2002) Haplotype combinations of calpain 10 gene polymorphisms associate with increased risk of impaired glucose tolerance and type 2 diabetes in South Indians. Diabetes 51:1622–1628
Busch CP, Ramdath DD, Ramsewak S, Hegele RA (1999) Association of PON2 variation with birth weight in Trinidadian neonates of South Asian ancestry. Pharmacogenetics 9:351–356
Chen Q, Reis SE, Kammerer CM, McNamara DM, Holubkov R, Sharaf BL, Sopko G, Pauly DF, Merz CN, Kamboh MI (2003) Association between the severity of angiographic coronary artery disease and paraoxonase gene polymorphisms in the National Heart, Lung, and Blood Institute-sponsored Women’s Ischemia Syndrome Evaluation (WISE) study. Am J Hum Genet 72:13–22
Pan JP, Lai ST, Chiang SC, Chou SC, Chiang AN (2002) The risk of coronary artery disease in population of Taiwan is associated with Cys-Ser 311 polymorphism of human paraoxonase (PON)-2 gene. Zhonghua Yi Xue Za Zhi (Taipei) 65:415–421
Pinizzotto M, Castillo E, Fiaux M, Temler E, Gaillard RC, Ruiz J (2001) Paraoxonase2 polymorphisms are associated with nephropathy in type II diabetes. Diabetologia 44:104–107
Kao YL, Donaghue K, Chan A, Knight J, Silink A (1998) A variant of paraoxonase (PON1) gene is associated with diabetic retinopathy in IDDM. J Clin Endocrinol Metab 83:2589–2592
Kordonouri O, James RW, Bennetts B, Chan A, Kao YL, Danne T, Silink M, Donaghue K (2001) Modulation by blood glucose levels of activity and concentration of paraoxonase in young patients with type 1 diabetes mellitus. Metabolism 50:657–660
Ikeda Y, Suehiro T, Inoue M, Nakauchi Y, Morita T, Arii K, Ito H, Kumon Y, Hashimoto K (1998) Serum paraoxonase activity and its relationship to diabetic complications in patients with non-insulin-dependent diabetes mellitus. Metabolism 47:598–602
Mackness B, Durrington PN, Abuashia B, Boulton AJ, Mackness MI (2000) Low paraoxonase activity in type II diabetes mellitus complicated by retinopathy. Clin Sci (Colch) 98:355–363
Araki S, Makita Y, Canani L, Ng D, Warram JH, Krolewski AS (2000) Polymorphisms of human paraoxonase 1 gene (PON1) and susceptibility to diabetic nephropathy in type I diabetes mellitus. Diabetologia 43:1540–1543
Canani LH, Araki S, Warram JH, Krolewski AS (2001) Comment-to: Pinizzotto M, Castillo E, Fiaux M, Temler E, Gaillard RC, Ruiz J (2001) Paraoxonase 2 polymorphisms are associated with diabetic nephropathy in type II diabetes. Diabetologia 44:104–107. Diabetologia 44:1062–1064
Kao Y, Donaghue KC, Chan A, Bennetts BH, Knight J, Silink M (2002) Paraoxonase gene cluster is a genetic marker for early microvascular complications in type 1 diabetes. Diabet Med 19:212–215
Carmine A, Buervenich S, Sydow O, Anvret M, Olson L (2002) Further evidence for an association of the paraoxonase 1 (PON1) Met-54 allele with Parkinson’s disease. Mov Disord 17:764–766
Akhmedova SN, Yakimovsky AK, Schwartz EI (2001) Paraoxonase 1 Met-Leu 54 polymorphism is associated with Parkinson’s disease. J Neurol Sci 184:179–182
Konda I, Yamamoto M (1998) Genetic polymorphism of paraoxonase 1 (PON1) and susceptibility to Parkinson’s disease. Brain Res 806:271–273
Wang J, Liu Z (2000) No association between paraoxonase 1 (PON1) gene polymorphisms and susceptibility to Parkinson’s disease in a Chinese population. Mov Disord 15:1265–1267
Dantoine TF, Drouet M, Debord J, Merle L, Cogne M, Charmes JP (2002) Paraoxonase 1 192/55 gene polymorphisms in Alzheimer’s disease. Ann N Y Acad Sci 977:239–244
Janka Z, Juhasz A, Rimanoczy AA, Boda K, Marki-Zay J, Kalman J (2002) Codon 311 (Cys→–Ser) polymorphism of paraoxonase-2 gene is associated with apolipoprotein E4 allele in both Alzheimer’s and vascular dementias. Mol Psychiatry 7:110–112
Zuliani G, Ble’ A, Zanca R, Munari MR, Zurlo A, Vavalle C, Atti AR, Fellin R (2001) Genetic polymorphisms in older subjects with vascular or Alzheimer’s dementia. Acta Neurol Scand 103:304–308
Nassar BA, Darvesh S, Bevin LD, Rockwood K, Kirkland SA, O’Neill BJ, Bata IR, Johnstone DE, Title LM (2002) Relation between butyrylcholinesterase K variant, paraoxonase 1 (PON1) Q and R and apolipoprotein E epsilon 4 genes in early-onset coronary artery disease. Clin Biochem 35:205–209
Herken H, Uz E, Ozyurt H, Sogut S, Virit O, Akyol O (2001) Evidence that the activities of erythrocyte free radical scavenging enzymes and the products of lipid peroxidation are increased in different forms of schizophrenia. Mol Psychiatry 6:66–73
Matsumoto C, Ohmori O, Hori H, Shinkai T, Nakamura J (2002) Analysis of association between the Gln192Arg polymorphism of the paraoxonase gene and schizophrenia in humans. Neurosci Lett 321:165–168
Barbieri M, Bonafe M, Marfella R, Ragno E, Giugliano D, Franceschi C, Paolisso G (2002) LL-paraoxonase genotype is associated with a more severe degree of homeostasis model assessment IR in healthy subjects. J Clin Endocrinol Metab 87:222–225
Kerridge I, Lincz L, Scorgie F, Hickey D, Granter N, Spencer A (2002) Association between xenobiotic gene polymorphisms and non-Hodgkin’s lymphoma risk. Br J Haematol 118:477–448
Draganov DI, Stetson PL, Watson CE, Billecke SS, La Du BN (2000) Rabbit serum paraoxonase 3 (PON3) is a high density lipoprotein-associated lactonase and protects low density lipoprotein against oxidation. J Biol Chem 275:33435–33442
Reddy ST, Wadleigh DJ, Grijalva V, Ng C, Hama S, Gangopadhyay A, Shih DM, Lusis AJ, Navab M, Fogelman AM (2001) Human paraoxonase-3 is an HDL-associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidized lipids. Arterioscler Thromb Vasc Biol 21:542–547
Heinecke JW, Lusis AJ (1998) Paraoxonase-gene polymorphisms associated with coronary heart disease: support for the oxidative damage hypothesis? Am J Hum Genet 62:20–24
Acknowledgements
This work is supported by “973” Basic Research Funding Scheme of China (G2000056902).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Li, HL., Liu, DP. & Liang, CC. Paraoxonase gene polymorphisms, oxidative stress, and diseases. J Mol Med 81, 766–779 (2003). https://doi.org/10.1007/s00109-003-0481-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00109-003-0481-4